Kodiak Sciences Inc. (KOD)

KOD earnings and analyst estimates

Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.

About Kodiak Sciences Inc.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.

KOD passes 1 of our 30 screens today

Each screen prints the exact criteria it used, and the circumstances in which it is wrong.

Super investor ownership

9 of the funds we track reported a position in their latest SEC 13F filing. Largest first:

• Two Sigma, TWO SIGMA INVESTMENTS, LP$18.43M · 0.0% of book
• D. E. Shaw, D. E. Shaw & Co., Inc.$8.23M · 0.0% of book
• Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$7.37M · 0.0% of book
• Ken Griffin, CITADEL ADVISORS LLC$6.14M · 0.0% of book
• Steve Cohen, Point72 Asset Management, L.P.$3.80M · 0.0% of book

A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.

Politician trades in KOD

Trades in KOD disclosed by members of Congress and executive-branch officials, latest first:

• Christopher L. Jacobs · HouseSell · $1,001 - $15,000 · traded 8 Nov 2022 · disclosed 12 Dec 2022
• Christopher L. Jacobs · HouseBuy · $1,001 - $15,000 · traded 18 Jul 2022 · disclosed 9 Sept 2022

A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.

KOD peers

The largest companies in the same industry (Biotechnology), then in the same sector.

• CSLLY CSL Limited
• RVMD Revolution Medicines, Inc.
• CMXHF CSL Limited
• ALNY Alnylam Pharmaceuticals, Inc.
• RPRX Royalty Pharma plc
• INCY Incyte Corporation
• INSM Insmed Incorporated
• GNMSF Genmab A/S

Every healthcare company we cover is on the Healthcare hub.

Common questions